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Integrins as signaling molecules and targets for tumor therapy. Adhe-
sion molecules include ligands and receptors. Together they provide cells
with anchorage and traction for migration, and the receptors also mediate
signals that control cell polarity, survival, growth, differentiation and gene
expression. Integrins are a major group of versatile adhesion receptors
that serve both adhesive and signaling functions. They possess shared and
unique specificies both outside and inside the cell. Many of the integrins
share an affinity toward the RGD recognition sequence in their extracel-
lular matrix ligands, but are still capable of distinguishing different
RGD-containing proteins. The shared signaling pathways are likely to
include changes in intracellular Ca2 and PIP2 concentrations, and the
activation of protein kinase C and focal adhesion kinase. Examples of
integrin-specific signaling include that the cs133 integrin (vitronectin
receptor) can potentiate the effects of insulin and certain other growth
factors and that the a.f3 integrin (fibronectin receptor) supports cell
survival in serum-free cultures by up-regulating the anti-apoptosis protein
Bcl-2. Another integrin function is that some integrins, in particular
are necessary for fibronectin matrix formation. Overexpression of 0513J,
which results in the assembly of additional fibronectin matrix, reduces
tumorigenicity of cultured tumor cells. Systemic treatment of tumor-
bearing mice with an artificially generated fibronectin matrix suppresses
metastasis. These and other findings indicate that the ligand binding and
signaling functions of integrins offer targets for new therapeutic ap-
proaches.
Cells adhere both to one another and to extracellular matrices.
These adhesive interactions are thought to play a major role in the
construction of the body plan of multicellular organisms during
development, because they can guide cells into their appropriate
locations in the body and anchor them there. Adhesion is also
important in the maintenance of the body plan; tumor cells are
able to loosen their attachment to leave their original location and
become lodged at distant sites. Adhesion molecules provide the
adhesive recognition specificities and signaling that are necessary
for these processes.
Integrins are an important family of adhesion proteins [1—31.
These large, heterodimeric membrane proteins are highly versa-
tile adhesion receptors; they anchor cells, provide traction for cell
migration and mediate signals. Integrins display specificity at
several levels. First, they are expressed in a cell-type and stage-
specific manner. Thus, one group of integrins is associated with
migration and proliferation in various types of cells. These
"emergency integrins" include cs5f31, cçj33 and csvP6. Many other
integrins are selectively expressed in a certain cell type or a few
cell types. Examples of cell-type specific integrins include alibi33
in platelets and aj34 in epithelial cells. Another level of integrin
specificity is manifested in their ligand binding. Many of the
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integrins bind the RGD cell attachment sequence, but they
recognize that sequence differentially in the context of various ext
racellular matrix proteins, such that some bind primarily to
fibronectin and others to vitronectin [3]. At yet another level of
specificity, individual integrins mediate distinct signals into the
cell's interior.
integrins have been shown to be signaling molecules capable of
generating both common signals and signals that are specific for
individual integrins. It has also been found that information can
flow in the reverse direction through integrins; their ligand
binding activity is regulated from the inside of the cell [4—6].
The increasing understanding of cell adhesion at the molecular
level has lead to a number of potential therapeutic applications.
The potential of these approaches ranges from implant technol-
ogies to anti-thrombotics and cancer treatments [7, 8].
In this article, I will review some new developments in integrin-
mediated signaling and matrix assembly. Potential therapeutic
applications of these observations will also be discussed.
Outside-in integrin signaling
Integrins communicate with the interior of the cells through
connections to the cytoskeleton and by transduction of signals.
Integrins are linked to actin filaments, and the link is thought to
be through talin, a-actinin and filamin [9—111. The cytoskeletal
binding may be responsible for some of the integrin signals, but
integrins also mediate chemical signaling. Moreover, the two
systems are interconnected. Some of the integrin-linked signaling
molecules, such as paxillin and cortactin [11, 12], are associated
with the cytoskeleton and the chemical signaling events elicited by
integrin-mediated cell attachment control cytoskeletal assembly
[13, 141. Some of the signaling pathways are common to a number
of integrins, whereas others appear to be specific for individual
integrins.
Signaling pathways shared by integrins
Integrins that mediate cell-extracellular matrix adhesion con-
nect the matrix to the intracellular cytoskeleton at focal adhe-
sions, which are punctate subcellular structures at the interface of
the cell and the substrate or the matrix. In addition to the
integrins, various signaling molecules assemble in focal adhesions,
resulting in the activation of a number of protein tyrosine kinases,
including focal adhesion kinase (FAK) and c-src. As a result, focal
adhesions are the main phosphotyrosine-containing structures in
the cell. The principal phosphoproteins in them include FAK,
p13OCs, a recently characterized docking protein, and certain
cytoskeleton-associated proteins such as paxillin and tensin [15—
17], which then transmit signals further to downstream pathways.
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Fig. 1. Schematic representation of integrin-specific cytoplasmic signaling pathways of the af3 and a531 integrins.
In addition, the pathways that appear not to be restricted to any
given integrin include increases in intracellular Ca2 and pH, and
the activation of the Ras, protein kinase C, phosphoinositol 3'
kinase and phosphoinositol 5' kinase pathways, and probably a
number of others as well [17].
One important function of the integrin signaling pathways is to
control anchorage dependence. This term refers to the require-
ment that normal adherent cells be attached to a substrate to be
able to grow. It has been realized recently that anchorage
dependence is an integrin-mediated phenomenon. Moreover, it
has also been shown that anchorage can mean the difference
between life and death to a cell. The early anchorage experiments
used fibroblasts, a cell type that becomes growth inhibited in
suspension, but remains viable. The new realization is that
epithelial and endothelial cells, when detached from substrate,
undergo apoptosis [18, 19]. This phenomenon has been named
anoikis [19]. To avoid anoikis these cell types will have to attach
to a substrate through integrins, attachment through other mem-
brane proteins cannot substitute for the integrins [18—20].
A central role for FAK anchorage dependence is suggested by
the recent finding that a constitutively activated FAK variant
confers to cells anchorage independence [211. Moreover, manip-
ulations that increase tyrosine phosphorylation, such as expression
of v-src or inhibition of phosphatase activity with vanadate,
circumvent the anchorage requirement [18, 19]. This is likely to be
the explanation for the relative independence from anchorage
characteristic of malignantly transformed cells, because onco-
genes provide the signals that the cell would otherwise have to
derive from substrate attachment.
Signaling by individual integrins
Relatively little attention has been paid to signaling pathways
that may be specific for individual integrins. The large cytoplasmic
tail of the a6/34 integrin /3 subunit, which is unique among the
integrins, has been shown to bind Shc. This adaptor protein
becomes tyrosine phophorylated in an a6/34-dependent manner
and is thought to couple the integrin to the Ras pathway through
another adaptor, Grb-2 [22]. The a/33 integrin has also been
found to be capable of activating Shc [23], but given the fact that
the /33 and /34 cytoplasmic tails are completely different, it is likely
that the mechanism of the Shc association, and probably its
consequences as well, are different for the two integrins. Our
laboratory has been working on two signaling systems that appear
to be specific for individual integrins, one for a/33 and the other
for a3 f3 (Fig. 1).
We have found that the a/33 integrin cooperates with IRS-i
[24]. IRS-i is a cytoplasmic signal transduction mediator of the
insulin (and insulin-like growth factor, IGF) receptors. IRS-i is
tyrosine-phosphorylated by the activated insulin (and IGF) recep-
tor and as a result binds a number of other signaling molecules
[25]. In cells that have adhered to a substrate (such as vitronectin)
through the cçj33 integrin, a subset of IRS-i binds to the integrin.
This interaction substantially enhances the growth-stimulating
effects of insulin and IGF. No other integrin among the several we
have tested interacts with the insulin/IRS-I system in this manner.
A 190 kDa protein that is phosphorylated in tyrosine as a result of
PDGF receptor activity also binds to a/33 [26], suggesting that
there may also be cooperation between this integrin and the
PDGF pathway. As the a,j33 integrin appears to be selectively
associated with endothelial cells undergoing angiogenesis [27], the
cooperation of this integrin with insulin could be of significance in
the neovascularization of tumors and inflammatory lesions, and in
the development of vascular complications of diabetes.
Another recently discovered pathway that also appears to be
specific for an individual integrin relates to the ability of the a5/31
integrin to protect cells against apoptosis under certain culture
conditions. Testing CHO cells that were engineered by cDNA
transfection to express either the a/31 or a/31 integrin as their
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fibronectin receptor, we found that only the cells that attached
through the a131 integrinsurvived in serum-free culture [281. This
response is associated with an elevated expression of the anti-
apoptosis protein Bcl-2. Thus, the a1J31 integrin provides a signal
for survival in serum-free culture and perhaps under other
stressful conditions. Integrins other than a5/31, including af31 [28]
or av/33 and various /3 integrins (unpublished results), fail to
rescue cells from apoptosis under these conditions, even though
they may support the attachment of the test cells. It is likely that
under other conditions cells depend on other integrins for survival
[27, 29]. Although we have tested a number of different cell lines
for their a5131 dependency and found them similar, it is also
possible that different cell types differ in their integrin dependence
under the same conditions. Integrin-mediated stimulation of
protease production appears to be coupled to a different integrin
in different cell types, a5131 in some cells and aj31 in others [30,
31]. A possible physiological significance of the integrin-selective
apoptosis phenomenon is that it may prevent cells from attaching
to inappropriate places in the body, because attachment through
a "wrong" integrin would induce apoptosis.
It will be important to elucidate these integrin-specific signaling
pathways at the molecular level. The a31 integrin pathways
would appear to be particularly important to work out because, as
discussed later on in this article, this integrin plays an important
role in malignancy.
Inside-out signaling: Regulation of integrin activity
Controlling the activity of integrins that are already expressed
at the cell surface provides a fast way for a cell to respond to
changing conditions. Thus, platelets effect their own aggregation
by activating the alibi33 integrin, which uses fibrinogen as the glue
to attach platelets to one another [5, 32]. Activation of 132 integrins
in leukocytes causes these cells to bind to vessel walls during
inflammation [61. Various types of adherent cells can also modu-
late the activity of their integrins. In some cases, activation can
change the ligand specificity of an integrin. Thus, the a2f31
integrin can be induced from being totally inactive to become
a collagen receptor and, further, to acquire the ability to bind
laminin [33].
The molecular mechanisms of integrin activation are not well
understood, but the process is thought to be mediated by the
integrin cytoplasmic domains and involve heterotrimeric G-pro-
teins, phospholipids and protein kinases [341. Protein kinase C is
required for integrins to be active, and activators of this kinase
activate integrin-mediated cell adhesion. Recently, a family of
cytoplasmic proteins, termed cytohesins, have been discovered
and implicated as regulators of 132 integrin ligand binding activity
[351 R-ras, a member of the Ras/Rho superfamily of small
GTPases, has been found to regulate the ligand binding of /3 and
a,, integrins [36]. Understanding the mechanisms of integrin
activity regulation will be an important goal for future research,
because the ability of adhesion receptors to be regulated in their
activity and specificity adds a great deal to the versatility of cell
adhesion and because integrin activity modulation could also have
therapeutic applications. The prevention of platelet aggregation
and leukocyte adhesion are obvious possibilities, but even regu-
lating the amount of fibronectin matrix deposition by cells may
be possible, at least under some special circumstances [37].
This latter possibility is an important one, because fibronectin
matrix and the main receptor for it, the a5131 integrin, appear to
play a key role in the control of the malignant properties of
tumor cells.
Effects of fibronectin matrix and a51 integrin on cells
Normal cells elaborate an extracellular matrix underneath and
around themselves. This matrix consists of a variety of proteins,
many of which are adhesive and mediate the anchorage of the
cells to the matrix. Fibronectin is a prototype adhesive protein
that is present in the matrix of many types of cells, where it
mediates cell adhesion through a number of fibronectin-binding
integrins, including a5/3.
Forced expression of the a5 131 integrin in tumor cells reduces
tumorigenicity [38, 39]. Conversely, a decrease in a5131 expression
increases the tumorigenicity of CHO cells [40]. a5/31 is the integrin
that controls the assembly of fibronectin matrix, and an increase in
a5/31 expression is accompanied by an increase in fibronectin
matrix assembly. We have attempted to determine whether the
tumor suppressor effect seen upon elevated a5 131 expression could
be reproduced with increased fibronectin matrix production.
We found a way of turning soluble fibronectin into fibrils
without involving the a5131 integrin. The fibril conversion was
induced by treating fibronectin with a small recombinant
fragment from the first type III repeat unit of fibronectin [41].
The mode of action of the fragment, referred to as 1111-C,
appears to be to interfere with the intramolecular binding
interactions that keep fibronectin in its soluble configuration.
Once those interactions are disrupted, the molecule undergoes
self-assembly into fibrils.
The activated fibronectin that results from the 1111-C treatment
is tenfold more adhesive to cells than fibronectin insolubilized
directly from solution, and hence this material is referred to as
superfibronectin (sFN). sFN inhibits cell migration in cell cultures
in a similar manner as a5131 overexpression, suggesting that at
least some of the a5131 effects on tumor cells are secondary to the
increased fibronectin matrix formation [41]. The latest results
show that sFN has striking anti-metastatic activities in vivo.
Treatment of tumor cells with sFN in vitro renders the cells
non-tumorigenic upon subsequent injection into mice. More
importantly, systemic treatment of mice with sFN strongly inhibits
spontaneous metastasis from subcutaneously implanted tumors
[8]. A wide variety of tumor types respond to sFN in this manner,
including human breast, colon and ovarian carcinoma, melanoma
and osteosarcoma implanted into nude mice. The mode of action
of sFN requires further study, but when used to treat cells in
suspension, it makes them incapable of adhering to any extracel-
lular matrix substrate [8]. We surmise that sFN may similarly coat
tumor cells that are in transit in vivo, preventing them from
attaching to the sites where metastases would otherwise form, and
that the tumor cells incapacitated in this manner would then be
susceptible to elimination by natural defense mechanisms. If this
postulated mechanism of action is correct, sFN would be acting in
the same way as RGD peptides, which inhibit ligand binding by
certain integrins [3] and have anti-metastatic activity [42]. How-
ever, direct comparison has shown that sFN is more potent in this
regard than the peptides [8].
Taken together, the observations discussed above suggest that
the fibronectin matrix is primarily responsible for the suppression
of malignant properties in cells expressing elevated levels of the
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a5f31 integrin. However, the effects of the matrix may in turn be
transmitted into the cell by a5f31, although this remains to be
demonstrated.
New therapeutic possibilities
One integrin-directed drug, an anti-/33 integrin antibody for the
prevention of arterial restenosis, has reached the marketplace so
far, but several other integrin-based drugs are under develop-
ment. For example, peptides containing the integrin-binding
RGD sequence [3], and mimics of such peptides that specifically
block individual integrins, are being developed as drugs. These
compounds target thrombosis (csllb!33 in platelets [7, 32]), osteo-
porosis (a.j33 in osteoclasts [43]) and tumor angiogenesis (af33 in
neovascular endothelial cells [44]). The anti-metastatic effect of
RGD peptides may offer another target. However, because the
metastasis work has been done with peptides that are not selective
for any individual integrin, it is not known which of the many
RGD-directed integrins mediates the antimetastatic effect. More-
over, as discussed above, sFN may be a more effective compound
for this particular application.
In summary, recent work on the integrins has greatly increased
our understanding of central cell biological phenomena, such as
anchorage dependence, as well as generated a number of possible
approaches to new therapies of cancer.
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